This project is only a blue print. No work has been done yet.
This helps diabetes patients by granting them the possiblity of receiving better and more customized treatment. It also enables physicians to monitor their patients closely without significant inconvenience to the patients.
Physicians will get better insights in their patients' behavior. Similar patients can be analyzed, and treatment plans can be developed for similar patients. This means that, within the bounds of privacy laws, knowledge can be shared among physicians. Because knowledge is power, additional data provides researchers with more opportunities to make meaningful innovations that enhances, improves, extends and saves the lives of diabetes patients.
Hospitals can treat more patients with less effort, fostering a higher cost efficiency. The analysis of patients and the optimization of treatment plans shared among a hospital network will be easier and cheaper. A hospital can grow a reputation of offering this solution as a cutting-edge facility taking a patient-centered approach in an increasingly "bespoke" and concierge health care culture.
Drug developers are able to gather insights from patients' behavior and can connect the dots between a patient's habits, the treatment plan and the outcome.
Every diabetes patient who currently receives treatment, this equals roughly 110 million Americans with either diabetes or prediabetes. Source: http://www.diabetes.org/diabetes-basics/statistics/?loc=db-slabnav
We intend to complete a testing period with a local hospital within the first year, and then roll out the application for production. Within one year, we intend a full roll-out within the Ochsner network. The possible market is about 30 million people within the U.S. for people who already struggle with diabetes and 80 million who are diagnosed with pre-diabetes. Within the first three years we aim at a market penetration of 10 percent, roughly 11 million people. Given we charge about $10 a person per month, this generates a revenue of $1.3 billion. Source: http://www.diabetes.org/diabetes-basics/statistics/?loc=db-slabnav
The application will generate revenue from license fees collected from health insurance and hospitals, currently aiming at $10 per diabetes patient monthly. Additionally, anonymized patient data may be sold to drug developers to develop better drugs.
Austria native Walter F. Gugenberger founded Flow Digital in 2017. Previously, he served as a software developer for an Austria-based logistics consulting company serving clients worldwide.
He completed his undergraduate studies at the University of Innsbruck, and he earned his Master’s degree in computer science from Johannes Kepler University in Linz, Austria. After an exchange year at the University of New Orleans, he fell in love with the city.
In his spare time, he enjoys traveling, exercising and cooking. He and his Louisiana native wife, Ellen, live in New Orleans.
No updates found .